Key Decisions and Financial Results

The Board of Directors of Paras Healthcare Limited met on November 05, 2026, from 5:30 PM to 6:08 PM IST and transacted the following business:

1. Approval of Financial Results: Based on the recommendations of the Audit Committee, the Board considered and approved the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026. The results were reviewed by the statutory auditors, M/s. Walker Chandiok & Co LLP (Firm Registration No. 001076N/N500013), who issued unmodified Limited Review Reports.

2. Continuation of Directorship: Based on the recommendations of the Nomination and Remuneration Committee, the Board approved the continuation of Mr. Kabir Kishin Thakur (DIN: 08422362) as a Non-Executive Non-Independent Director under Regulation 17(1D) of the SEBI Listing Regulations, subject to the approval of the shareholders. It was confirmed that he is not debarred from holding the office of director by any SEBI Order or authority.

Detailed Financial Performance (Consolidated)

Income Statement Highlights (₹ in millions)

For the Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from operations: ₹5,108.95
  • Other income: ₹64.52
  • Total Income: ₹5,173.47
  • Total Expenses: ₹4,631.28
  • Profit before tax: ₹542.19
  • Tax expense: ₹138.69 (Current tax: ₹154.24; Deferred tax credit: ₹(15.55))
  • Profit for the period: ₹403.50
  • Total Comprehensive Income: ₹404.89
  • Earnings Per Share (Basic & Diluted): ₹4.00

For the Six Months Ended September 30, 2026 (H1 FY27):

  • Revenue from operations: ₹9,811.73
  • Other income: ₹149.20
  • Total Income: ₹9,960.93
  • Total Expenses: ₹8,937.54
  • Profit before tax: ₹1,023.39
  • Tax expense: ₹123.07 (Current tax: ₹300.79; Deferred tax credit: ₹(177.72))
  • Profit for the period: ₹900.32
  • Total Comprehensive Income: ₹897.55
  • Earnings Per Share (Basic & Diluted): ₹8.92

Comparative Figures (H1 FY26):

  • Profit for the period (H1 FY26): ₹113.65
  • EPS (H1 FY26): ₹1.13

Balance Sheet Highlights (Consolidated as of September 30, 2026)

  • Total Assets: ₹23,157.73 million
  • Non-current assets: ₹13,668.64 million (including Property, plant and equipment: ₹6,513.87 million; Right-of-use assets: ₹5,213.51 million)
  • Current assets: ₹9,489.09 million (including Trade receivables: ₹5,178.97 million; Cash and cash equivalents: ₹445.49 million; Bank balances other than cash: ₹2,613.86 million)
  • Total Equity: ₹4,861.47 million
  • Equity share capital: ₹100.99 million (face value ₹1 each)
  • Other equity: ₹4,760.48 million
  • Total Liabilities: ₹18,296.26 million
  • Non-current liabilities: ₹9,937.96 million (including Borrowings: ₹4,764.94 million; Lease liabilities: ₹5,054.25 million)
  • Current liabilities: ₹8,358.30 million (including Borrowings: ₹5,025.11 million; Lease liabilities: ₹362.67 million; Trade payables: ₹2,472.33 million)

Cash Flow Highlights (Consolidated for H1 FY27)

  • Net cash from operating activities: ₹681.71 million
  • Net cash used in investing activities: ₹(1,338.74) million
  • Net cash from financing activities: ₹630.47 million
  • Net decrease in cash and cash equivalents: ₹(26.56) million

Detailed Financial Performance (Standalone)

Income Statement Highlights (₹ in millions)

For the Quarter Ended September 30, 2026 (Q2 FY27):

  • Revenue from operations: ₹4,129.71
  • Other income: ₹144.52
  • Total Income: ₹4,274.23
  • Total Expenses: ₹3,747.04
  • Profit before tax: ₹527.19
  • Tax expense: ₹135.43 (Current tax: ₹154.24; Deferred tax credit: ₹(18.81))
  • Profit for the period: ₹391.76
  • Total Comprehensive Income: ₹393.07
  • Earnings Per Share (Basic & Diluted): ₹3.88

For the Six Months Ended September 30, 2026 (H1 FY27):

  • Revenue from operations: ₹7,995.88
  • Other income: ₹304.87
  • Total Income: ₹8,300.75
  • Total Expenses: ₹7,280.66
  • Profit before tax: ₹1,020.09
  • Tax expense: ₹260.92 (Current tax: ₹300.79; Deferred tax credit: ₹(39.87))
  • Profit for the period: ₹759.17
  • Total Comprehensive Income: ₹756.71
  • Earnings Per Share (Basic & Diluted): ₹7.52

Balance Sheet Highlights (Standalone as of September 30, 2026)

  • Total Assets: ₹23,298.98 million
  • Total Equity: ₹7,651.40 million
  • Equity share capital: ₹100.99 million
  • Other equity: ₹7,550.41 million
  • Total Liabilities: ₹15,647.58 million

Subsidiary Information

The consolidated results include the following wholly-owned subsidiaries:

1. Paras Healthcare (Ranchi) Private Limited

2. Plus Medicare Hospitals Private Limited

Subsequent Event: IPO Completion and Utilization of Proceeds

Subsequent to September 30, 2026, the company completed its Initial Public Offering (IPO).

  • IPO Details: Issued 20,923,520 equity shares of face value ₹1 each at a price of ₹693 per share, aggregating ₹14,500.00 million.
  • IPO Structure: Comprised a fresh issue of 7,215,007 shares (₹5,000.00 million) and an offer for sale of 13,708,513 shares (₹9,500.00 million) by selling shareholders.
  • Listing: Equity shares were listed on NSE and BSE with effect from October 28, 2026.
  • Proceeds Utilization: As of the date of these results (November 05, 2026), ₹3,750.00 million from the fresh issue proceeds of ₹5,000.00 million has been utilized towards repayment/prepayment of certain borrowings of the Holding Company and its subsidiary, in line with the objects stated in the Prospectus. The issue proceeds are subject to adjustment for offer expenses.

Director Information: Mr. Kabir Kishin Thakur

  • DIN: 08422362
  • Role: Non-Executive Non-Independent Director (continuation approved, subject to shareholder approval)
  • Profile: Holds a bachelor's in commerce and a Master of Management Studies from the University of Mumbai. Has over 19 years of experience in investment and private equity, previously associated with ChrysCapital Group as a director and Citibank's investment banking division. Currently the designated partner of CR Advisors LLP and Creador Conscienta LLP.
  • Relationship: Not related to any other directors of the company.